News
Fullpower-AI receives Sleeptracker-AI Validation in world-leading medical journal, Sleep Medicine
Fullpower-AI is proud to have the world-leading medical sleep journal publish a validation of the Sleeptracker-AI platform.
Sleep Medicine is including the publication “Polysomnographic validation of an under-mattress monitoring device in estimating sleep architecture and obstructive sleep apnea in adults.” In the publication, Dr. Kushida, Medical Director of Stanford Sleep Medicine, validates the accuracy of the Sleeptracker-AI solution. Dr. Kushida, MD, Ph.D., FAASM, principal investigator of this study, concludes:
“The Sleeptracker-AI Monitor had high accuracy, sensitivity, and specificity in estimating sleep continuity measures and sleep architecture, as well as in estimating apnea and hypopnea.
These findings indicate that Sleeptracker-AI Monitor is a valid device for monitoring sleep quantity and quality among adults. Sleeptracker-AI Monitor may also be a reliable complementary tool to PSG for OSA screening in clinical practice.”
The publication and validation are available here:
https://www.sciencedirect.com/science/article/pii/S1389945722001368
Dr. Kushida’s Biography:
https://profiles.stanford.edu/clete-kushida
More information at
https://sleeptracker-ai.com
About Fullpower-AI®
Fullpower-AI® delivers the KOA platform, an enterprise-grade LAM (Large Action Model) biosensing solution engineered to scale specialised conversational and generative AI for the health, wellness, senior living, and sleep science sectors. Purpose-built for providers, KOA deploys autonomous AI agents with real-time reasoning, adaptive learning, and actionable intelligence across all communication channels. These human-like agents enable fast, personalized, and context-aware interactions while seamlessly aggregating and analyzing data from all major wearables and contactless sensors. By managing routine tasks and queries, KOA empowers care teams to focus on complex needs and meaningful resident engagement. Stanford Medicine and UCSF independently vet our platform.